Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstrated Meaningful Clinical Improvement Company Plans to Meet with FDA to Discuss Next Steps for this Breakthrough Therapy NEW YORK, July 27, 2018 (GLOBE …